Meeting
2019 ASCO Annual Meeting
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Authors
Thomas Yau
The University at Hong Kong, Hong Kong, China
Thomas Yau , Yoon-Koo Kang , Tae-You Kim , Anthony B. El-Khoueiry , Armando Santoro , Bruno Sangro , Ignacio Melero , Masatoshi Kudo , Ming-Mo Hou , Ana Matilla , Francesco Tovoli , Jennifer J. Knox , Aiwu Ruth He , Bassel F. El-Rayes , Mirelis Acosta-Rivera , Jaclyn Neely , Yun Shen , Carlos Baccan , Christine Marie Dela Cruz , Chiun Hsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01658878
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4012)
DOI
10.1200/JCO.2019.37.15_suppl.4012
Abstract #
4012
Poster Bd #
117
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
First Author: Aiwu Ruth He
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
First Author: Todd S. Crocenzi
Poster
2017 Gastrointestinal Cancers Symposium
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
First Author: Ignacio Melero
Poster
2021 Gastrointestinal Cancers Symposium
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
First Author: Jeffrey Sum Lung Wong